GT200100169A - Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2. - Google Patents
Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2.Info
- Publication number
- GT200100169A GT200100169A GT200100169A GT200100169A GT200100169A GT 200100169 A GT200100169 A GT 200100169A GT 200100169 A GT200100169 A GT 200100169A GT 200100169 A GT200100169 A GT 200100169A GT 200100169 A GT200100169 A GT 200100169A
- Authority
- GT
- Guatemala
- Prior art keywords
- hadh2
- erab
- activity
- methods
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
EN LA PRESENTE INVENCION SE DESCRIBEN COMPUESTOS QUIMICOS REPRESENTADOS POR LA FORMULA (I), EN DONDE R, R6, X E Y SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS PUEDEN SER UTILIZADOS EN LA INHIBICION DE LA ACTIVIDAD DE ERAB/HADH2 Y/O EN EL TRATAMIENTO DE LAS ENFERMEDADES Y AFECCIONES MEDIADAS POR ERAB/HADH2. ADEMAS LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS TERAPEUTICOS, COMPOSICIONES, Y METODOS UTILIZADOS PARA TRATAR LAS ENFERMEDADES NEURO DEGENERATIVAS Y CIERTAS NEOPLASIAS MALIGNAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22612300P | 2000-08-18 | 2000-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200100169A true GT200100169A (es) | 2002-05-16 |
Family
ID=22847647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200100169A GT200100169A (es) | 2000-08-18 | 2001-08-17 | Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2. |
Country Status (14)
Country | Link |
---|---|
US (2) | US6964957B2 (es) |
EP (2) | EP1311511A1 (es) |
JP (2) | JP2004506737A (es) |
AR (1) | AR035486A1 (es) |
AU (1) | AU2001296854A1 (es) |
BR (1) | BR0113461A (es) |
CA (2) | CA2354653A1 (es) |
GT (1) | GT200100169A (es) |
HK (1) | HK1046288A1 (es) |
MX (1) | MXPA03001455A (es) |
PA (1) | PA8525801A1 (es) |
PE (1) | PE20020394A1 (es) |
UY (1) | UY26895A1 (es) |
WO (1) | WO2002016365A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10221052A1 (de) * | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
CA2565308A1 (en) * | 2003-05-06 | 2004-11-25 | New Century Pharmaceuticals | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
WO2005041895A2 (en) * | 2003-11-03 | 2005-05-12 | New Century Pharmaceuticals, Inc. | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
US20080274975A1 (en) * | 2004-04-12 | 2008-11-06 | The Trustees Of Columbia University In The City Of New Yourk | Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction |
CA2583439C (en) * | 2004-09-24 | 2016-05-10 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
US9932351B2 (en) | 2015-02-05 | 2018-04-03 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2023146880A1 (en) * | 2022-01-25 | 2023-08-03 | Board Of Regents Of The University Of Nebraska | Functionalized allopurinol derivatives for treatment of alzheimer's disease |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3165520A (en) | 1965-01-12 | Certificate of correction | ||
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
DE68908786T2 (de) | 1988-06-16 | 1994-03-17 | Smith Kline French Lab | Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. |
US5109119A (en) * | 1989-06-06 | 1992-04-28 | Schering Corporation | Crystalline r-h-gm-csf and method |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5322933A (en) * | 1992-05-07 | 1994-06-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Crystal structure of TGF-β-2 |
PH31122A (en) | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
US5294611A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5556778A (en) * | 1994-04-28 | 1996-09-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Crystalline Inha Enzyme-NADH Complex |
CN1056611C (zh) | 1994-06-16 | 2000-09-20 | 美国辉瑞有限公司 | 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体 |
US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US6153652A (en) | 1996-11-22 | 2000-11-28 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6268479B1 (en) * | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
BR9808845A (pt) | 1997-03-14 | 2000-08-01 | Otsuka Pharma Co Ltd | Derivado de pirimidina, agentes para a cura de uma doença alérgica, da asma e de uma dermatite atópica, agentes para inibição da produção de no de tnf-alfa, de citoquinas e da 5-lipoxigenase, processos para curar uma doença alérgica, a asma e uma dermatite atópica e para inibir a produção de no, de tnf-alfa e de citoquinas e a 5-lipoxigenase e usos de um composto |
PL336586A1 (en) | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
US6020162A (en) * | 1997-06-13 | 2000-02-01 | The Rockefeller University | Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof |
US5872011A (en) * | 1997-06-13 | 1999-02-16 | The Rockefeller University | Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof |
ATE355841T1 (de) | 1997-12-13 | 2007-03-15 | Bristol Myers Squibb Co | Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9822238D0 (en) | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
AUPP672198A0 (en) | 1998-10-23 | 1998-11-19 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
MXPA01011112A (es) | 1999-06-10 | 2002-06-04 | Warner Lambert Co | Metodo para la inhibicion de la agregacion de las proteinas amiloides y formacion de imagenes de los depositos amiloides utilizando derivados de la isoindolina. |
MXPA01009863A (es) | 1999-06-10 | 2002-05-06 | Warner Lambert Co | Derivados de rodanina y su uso en la inhibicion y formacion de imagenes amiloides. |
BR0011441A (pt) | 1999-06-10 | 2002-07-16 | Warner Lambert Co | Derivados de rodanina para uso em um método de inibição da agregação da proteìna amilóide e formação de imagens de depósitos amilóides |
CA2382095A1 (en) | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
-
2001
- 2001-08-16 PE PE2001000819A patent/PE20020394A1/es not_active Application Discontinuation
- 2001-08-17 AU AU2001296854A patent/AU2001296854A1/en not_active Abandoned
- 2001-08-17 US US09/931,166 patent/US6964957B2/en not_active Expired - Fee Related
- 2001-08-17 GT GT200100169A patent/GT200100169A/es unknown
- 2001-08-17 PA PA20018525801A patent/PA8525801A1/es unknown
- 2001-08-17 AR ARP010103959A patent/AR035486A1/es not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/041795 patent/WO2002016365A1/en not_active Application Discontinuation
- 2001-08-17 MX MXPA03001455A patent/MXPA03001455A/es unknown
- 2001-08-17 CA CA002354653A patent/CA2354653A1/en not_active Abandoned
- 2001-08-17 US US09/931,186 patent/US20020132319A1/en not_active Abandoned
- 2001-08-17 EP EP01977762A patent/EP1311511A1/en not_active Withdrawn
- 2001-08-17 CA CA002415182A patent/CA2415182A1/en not_active Abandoned
- 2001-08-17 BR BR0113461-2A patent/BR0113461A/pt not_active IP Right Cessation
- 2001-08-17 UY UY26895A patent/UY26895A1/es not_active Application Discontinuation
- 2001-08-17 JP JP2002521466A patent/JP2004506737A/ja not_active Withdrawn
- 2001-08-20 EP EP01307075A patent/EP1223176A3/en not_active Withdrawn
- 2001-08-20 JP JP2001249448A patent/JP2002360269A/ja active Pending
-
2002
- 2002-10-15 HK HK02107461.3A patent/HK1046288A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2354653A1 (en) | 2002-02-18 |
BR0113461A (pt) | 2003-07-01 |
PE20020394A1 (es) | 2002-06-21 |
AU2001296854A1 (en) | 2002-03-04 |
EP1223176A2 (en) | 2002-07-17 |
JP2002360269A (ja) | 2002-12-17 |
EP1311511A1 (en) | 2003-05-21 |
PA8525801A1 (es) | 2002-08-29 |
EP1223176A3 (en) | 2002-10-23 |
UY26895A1 (es) | 2002-04-26 |
HK1046288A1 (zh) | 2003-01-03 |
WO2002016365A1 (en) | 2002-02-28 |
MXPA03001455A (es) | 2004-05-04 |
CA2415182A1 (en) | 2002-02-28 |
JP2004506737A (ja) | 2004-03-04 |
AR035486A1 (es) | 2004-06-02 |
US20020065292A1 (en) | 2002-05-30 |
US6964957B2 (en) | 2005-11-15 |
US20020132319A1 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200100137A (es) | Pro-drogas de derivados de 4-fenil-piridina. | |
ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
NO20042298L (no) | Farmasoytiske preparater og deres anvendelser | |
EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
GT200100169A (es) | Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2. | |
CR7785A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
ES2191069T3 (es) | Diaril-2-(5h)-furanonas como inhibidores de cox-2. | |
BRPI0408990A (pt) | derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase | |
BRPI0413580A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp | |
PT1259512E (pt) | Compostos de pteridin para o tratamento da psoriase | |
EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
EE200200625A (et) | Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena | |
BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
ATE432936T1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
HUP0201282A2 (hu) | Hatóanyagként kinazolindionszármazék kimázinhibitort tartalmazó gyógyászati készítmények dermatitisz megelőzésére és kezelésére | |
ATE296814T1 (de) | Ionenkanal modulierende mittel | |
DE69822937D1 (de) | Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen | |
ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz |